The impact of ertapenem use on the susceptibility of pseudomonas aeruginosa to imipenem: A hospital case study

Infection Control and Hospital Epidemiology

Volumn 30, Issue 5, 2009, Pages 487-490

  Lima, Ana Lucia L ^a,c   Oliveira, Priscila R ^a   Paula, Adriana P ^a   Dal Paz, Karine ^a   Rossi, Flavia ^b   Zumiotti, Arnaldo V ^a  

^a Institute of Orthopedics and Traumatology   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; ERTAPENEM; IMIPENEM; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SENSITIVITY; ENTEROBACTERIACEAE INFECTION; HOSPITAL INFECTION; NONHUMAN; PSEUDOMONAS AERUGINOSA; ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; BRAZIL; CROSS INFECTION; DRUG EFFECT; DRUG UTILIZATION; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PSEUDOMONAS INFECTION; STATISTICS; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; BRAZIL; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 67649710785     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/596781     Document Type: Article

References (11)

1. European Antimicrobial Resistance Surveillance System. Dutch National Institute for Public Health and the Environment (RIVM) annual reports. Available at: http://www.rivm.nl/earss/result/Monitoring-reports/Annual-reports.jsp. Accessed May 5, 2008.
2. Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005; 26:463-472.
3. Shah P, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52:538-542.
4. Livermore D, Mushtaq S, Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 2005; 55:306-311.
5. Brink A, Feldman C, Grolman DC, et al. Appropriate use of the carbapenems. S Afr Med J 2004; 94:857-861.
6. Rossi F, Baguero F, Hsueh P, et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006; 58:205-210.
7. DiNubile M, Friedland I, Chan CY, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005; 24:443-449.
8. Goff DA, Mangino J. Ertapenem: no effect on gram-negative susceptibilities to imipenem. J Infect 2008; 57:123-127.
9. Lima AL, Oliveira PR, Paula AP, et al. Influence of ertapenem administration on the incidence of carbapenem-resistant Pseudomonas aeruginosa. Braz J Infect Dis 2008; 12:105-106.
10. Marra AR, Wey SB, Castelo A, et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infectious Diseases 2006; 6:24-31.
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne, PA: CLSI, 2006:M100-S16.